Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.

Employees

Sector

Environmental Services & Equipment

More about the company

Quotes

Date	Price	Change	Volume
26-09-16	US$0.000001	0.00%	620,483

End-of-day quote OTC Markets

More quotes

End-of-day quote OTC Markets 2026-09-16			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-

24-03-25	Infinity Pharmaceuticals, Inc. Went Out of Business	CI
24-03-06	Revised Liquidation Plan Approved for Infinity Pharmaceuticals, Inc.	CI

Market Cap	227K 198K 187K 170K 318K 21.77M 319K 2.24M 864K 11.07M 852K 833K 35.62M	P/E 2021	-4.25x	P/E 2022	-1.11x
Enterprise Value	11.26M 9.82M 9.27M 8.42M 15.78M 1.08B 15.84M 111M 42.86M 549M 42.31M 41.37M 1.77B	EV / Sales 2021	91.8x	EV / Sales 2022	23.4x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

24-03-25	Infinity Pharmaceuticals, Inc. Went Out of Business	CI
24-03-06	Revised Liquidation Plan Approved for Infinity Pharmaceuticals, Inc.	CI
24-02-21	Motion for Di Minimis Assets Sale Approved for Infinity Pharmaceuticals, Inc.	CI
24-02-14	An unknown healthcare investment firm acquired Substantially all of the assets of Infinity Pharmaceuticals, Inc. (OTCPK:INFI.Q).	CI
24-02-12	First Motion for Exclusivity Period Extension Approved For Infinity Pharmaceuticals, Inc.	CI
24-02-01	Disclosure Statement Approved on Interim Basis for Infinity Pharmaceuticals, Inc.	CI
24-01-25	First Motion for Exclusivity Period Extension Filed by Infinity Pharmaceuticals, Inc.	CI
24-01-10	Joint Liquidation Plan and Disclsoure Statement Filed by Infinity Pharmaceuticals, Inc.	CI
24-01-07	Motion for Asset Sale Approved for Infinity Pharmaceuticals, Inc.	CI
23-10-23	Bidding Procedure Approved for Infinity Pharmaceuticals, Inc.	CI
23-10-02	Motion for Joint Administration Approved for Infinity Pharmaceuticals, Inc.	CI
23-09-29	Infinity Pharmaceuticals, Inc. Announces Resignation of Adelene Perkins from the Board	CI
23-09-29	INFINITY PHARMACEUTICALS LISTS BOTH ESTIMATED ASSETS AND LIABILI…	RE

23-02-24	Piper Sandler Downgrades Infinity Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $0.30 From $3	MT
22-11-15	B. Riley Downgrades Infinity Pharmaceuticals to Neutral From Buy, Lowers PT to $1.50 From $3; Moves to Sidelines Until Partner Helps Advance Eganelisib	MT
22-08-15	JonesTrading Downgrades Infinity Pharmaceuticals to Hold From Buy	MT
22-08-10	B. Riley Lowers Infinity Pharmaceuticals' Price Target to $3 from $5 to Reflect Delay in Eganelisib's Development, Uncertainty on Timing of Partnership; Maintains Buy Rating	MT
22-05-23	Piper Sandler Adjusts Infinity Pharmaceuticals' Price Target to $3 from $4, Keeps Overweight Rating	MT

Infinity Pharmaceuticals, Inc. Stock

Stocks

INFI.Q

US45665G3039

Environmental Services & Equipment

Valuation: Infinity Pharmaceuticals, Inc.

Chart: Infinity Pharmaceuticals, Inc.

Latest news: Infinity Pharmaceuticals, Inc.

Analysts' recommendations: Infinity Pharmaceuticals, Inc.

Press Releases: Infinity Pharmaceuticals, Inc.

News in other languages: Infinity Pharmaceuticals, Inc.

Price Extremes

Latest insider transactions

Other Environmental Services & Equipment

Financials

Company Profile

Quotes

24-05-14	Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	AQ
23-12-05	Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	AQ
23-09-29	Infinity Pharmaceuticals : Bankruptcy - Form 8-K	PU
23-08-18	INFINITY ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Infinity Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm	BU
23-07-25	Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan	BU

15-01-08	BIND Therapeutics : Les valeurs à suivre sur les marchés américains.
15-01-08	USA-Les valeurs à suivre à Wall Street

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.02
5 years	0		3.76
10 years	0		5.98

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/8/23	Adelene Perkins	Exercice	Chief Executive Officer	1,946,462	2.1446%
8/2/22	Stéphane Peluso	Exercice	Chief Technology Officer	114,994	0.1290%
6/16/22	David Beier	Free	Director	45,000	0.0505%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INFINITY PHARMACEUTICALS, INC.	0.00%	0.00%	-98.00%	-100.00%	90
WASTE MANAGEMENT, INC.	-1.05%	-1.11%	-2.45%	+31.90%	84.38B
REPUBLIC SERVICES, INC.	-0.39%	-2.10%	-3.91%	+46.06%	66.78B
VERALTO CORPORATION	-0.80%	+0.41%	-11.61%	-	23.04B
CLEAN HARBORS, INC.	+0.08%	-2.17%	+34.64%	+86.58%	16.67B
TETRA TECH, INC.	-1.18%	-2.21%	-1.04%	+13.52%	9.14B
FOMENTO DE CONSTRUCCIONES Y CONTRATAS, S.A.	-1.12%	-1.86%	-4.00%	-10.96%	5.73B
KURITA WATER INDUSTRIES LTD.	+1.15%	+3.05%	+46.35%	+41.65%	5.23B
INFORE ENVIRONMENT TECHNOLOGY GROUP CO., LTD.	+2.48%	+3.25%	+15.04%	+67.89%	4.1B
ZIJIN LONGKING CO., LTD.	-0.17%	-0.96%	+27.47%	+14.58%	3.29B
Average	-0.10%	-0.24%	+0.25%	+21.25%	21.83B
Weighted average by Cap.	-0.61%	-1.11%	+0.94%	+40.02%

	2021	2022
Net sales	1.86M 1.62M 1.53M 1.39M 2.6M 178M 2.61M 18.33M 7.07M 90.64M 6.98M 6.82M 292M	2.59M 2.26M 2.13M 1.94M 3.63M 249M 3.65M 25.57M 9.87M 126M 9.74M 9.52M 407M
Net income	-45.26M -39.47M -37.27M -33.84M -63.41M -4.34B -63.67M -446M -172M -2.21B -170M -166M -7.1B	-44.37M -38.69M -36.53M -33.17M -62.15M -4.26B -62.41M -438M -169M -2.16B -167M -163M -6.96B
Net Debt	-29.67M -25.87M -24.43M -22.18M -41.56M -2.85B -41.73M -293M -113M -1.45B -111M -109M -4.66B	11.04M 9.62M 9.09M 8.25M 15.46M 1.06B 15.52M 109M 42M 538M 41.45M 40.53M 1.73B